Free tool
FAERS Monitor: Gozellix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219592 or its brand name (Gozellix, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.
Reports
18
Serious
0
0% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain13
- dizziness2
- chest pain1
- dysarthria1
- hyperhidrosis1
- hypersensitivity1
- hypoaesthesia1
- injection site urticaria1
- nausea1
- vomiting1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site painSignal | 13 | 49.5 | 37.2 | 579 |
| injection site urticaria | 1 | 47.6 | 7.1 | 11 |
| dysarthria | 1 | 31.0 | 4.6 | 7 |
| hyperhidrosis | 1 | 9.1 | 1.4 | 1 |
| hypoaesthesia | 1 | 7.8 | 1.2 | 1 |
| chest pain | 1 | 6.3 | 0.9 | 1 |
| hypersensitivity | 1 | 6.3 | 0.9 | 1 |
| dizziness | 2 | 4.7 | 1.3 | 3 |
| vomiting | 1 | 2.5 | 0.4 | 0 |
| nausea | 1 | 1.5 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.